Drug Search Results
More Filters [+]

Rasagiline

Alternative Names: rasagiline, azilect, tvp-1012, HNC364, HNC-364, HNC 364, rasagilintartrat, rasagilin
Latest Update: 2024-09-27
Latest Update Note: Clinical Trial Update

Product Description

Rasagiline (Azilect(®)) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson's disease.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25322951/)

Mechanisms of Action: MAO-b Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rasagiline

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HNC364-A101

P1

Completed

Parkinson's Disease

2024-04-15

CTR20231500

P1

Recruiting

Parkinson's Disease

None

Recent News Events